Silent suppression for Antisense
Wednesday, 15 October, 2008
Preclinical trials of Antisense Therapeutics’ [ASX: ANP] ATL1101 candidate have been shown to suppress human prostate tumour growth in animal models.
ATL1101 suppressed the growth of human tumours in mice that had been implanted with human prostate cancer sells.
The treatment slowed down the cancerous cells' transition to the most dangerous form of prostate cancer, castration-resistant prostate cancer [CRPC].
The study was conducted with the assistance of Martin Gleave, the director of the Prostate Centre at Vancouver General Hospital.
This is the first known demonstration of the efficacy of RNA-silencing IGF-I receptor drugs in prostate cancer models.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
